BRCA2 and cancer: In addition to cancer family history and single personal criteria related to early onset or phenotype, testing criteria for BRCA1 and BRCA2 genes have been expanded over time to optimize identification of putative patients who might benefit from active therapies that create DNA double-strand breaks or stalled replication forks, such as the platinum salts or PARPi.